Gerald S Horan, Susan Wood, Victor Ona, Dan Jun Li, Matvey E Lukashev, Paul H Weinreb, Kenneth J Simon, Kyungmin Hahm, Normand E Allaire, Nicola J Rinaldi, Jaya Goyal, Carol A Feghali-Bostwick, Eric L Matteson, Carl O'Hara, Robert Lafyatis, Gerald S Davis, Xiaozhu Huang, Dean Sheppard, Shelia M Violette
RATIONALE: Transforming growth factor (TGF)-beta has a central role in driving many of the pathological processes that characterize pulmonary fibrosis. Inhibition of the integrin alpha(v)beta6, a key activator of TGF-beta in lung, is an attractive therapeutic strategy, as it may be possible to inhibit TGF-beta at sites of alpha(v)beta6 up-regulation without affecting other homeostatic roles of TGF-beta. OBJECTIVES: To analyze the expression of alpha(v)beta6 in human pulmonary fibrosis, and to functionally test the efficacy of therapeutic inhibition of alpha(v)beta6-mediated TGF-beta activation in murine bleomycin-induced pulmonary fibrosis...
January 1, 2008: American Journal of Respiratory and Critical Care Medicine